SpecGx LLC has secured FDA approval for the generic oral formulation of Diphenoxylate Hydrochloride and Atropine Sulfate, positioning the company to enter the market and increase competition within the branded antidiarrheal segment. This clearance is expected to foster pricing pressure, thereby lowering costs and improving patient access to treatment.